Recent developments for Celularity include a licensing and asset sale agreement with NexGel for biomaterial products, partnerships to provide stem cell therapies under new Florida laws, management changes, Nasdaq compliance resolutions, and reported financial performance for 2024 and 2025.

• On March 6, 2026, Celularity entered into an Asset Purchase and Exclusive License Agreement with NexGel to license and sell six biomaterial products, with amended consideration totaling $13.3 million including upfront cash and a convertible promissory note [N2].
• Celularity's Biovance and Biovance 3L products remain eligible for medical coverage under withdrawn Local Coverage Determinations as of December 29, 2025 [N3].
• The company partnered with Fountain Life to provide stem cell therapies following new Florida legislation authorizing such treatments for physicians [N4][N5].
• In June 2025, Celularity announced termination of CFO David Beers and appointed Joseph DosSantos as interim CFO [N6].
• Celularity was notified by Nasdaq of non-compliance with quarterly filing requirements in May 2025 but subsequently resolved listing compliance matters and resumed timely quarterly submissions by December 2024 [N7].
• The company reported strong financial growth and increased revenue for the year ended December 31, 2024 [N8].
• Celularity faced potential delisting from Nasdaq due to fee and filing delinquencies in April 2025 but announced resolution of the listing compliance matter in December 2024 [N7].
• Recent news also includes general market movements unrelated to Celularity [N1].

Celularity's unique focus on placental-derived allogeneic cellular therapies targeting core biological drivers of aging positions it in a growing longevity-focused therapeutic landscape. Its integrated Celularity IMPACT platform and proprietary manufacturing capabilities could enable efficient, scalable production of off-the-shelf therapies with potential advantages in efficacy and tolerability. The company's commercial biomaterial products provide a revenue base and opportunities for pipeline expansion. Partnerships and licensing agreements, such as with NexGel and Fountain Life, demonstrate strategic efforts to monetize assets and expand market reach. Successful advancement of clinical programs and regulatory approvals could enhance the company's position in regenerative medicine and aging-related disease treatment.

Celularity faces significant financial challenges, including substantial net losses, limited cash reserves, and liquidity ratios indicating difficulty in meeting short-term obligations, raising substantial doubt about its ability to continue as a going concern without additional financing. The company has experienced Nasdaq compliance issues and management changes, which may impact operational stability. The highly speculative nature of biopharmaceutical development, regulatory uncertainties, and competitive pressures in regenerative medicine add to execution risks. Failure to secure sufficient capital or achieve clinical and commercial milestones could materially impair the company's business and financial condition.

Celularity's moat is based on its proprietary Celularity IMPACT platform that integrates end-to-end manufacturing of placental-derived allogeneic cellular therapies, leveraging unique biological advantages of placental cells such as greater stemness, immunological naivete, and off-the-shelf availability. The company's extensive biobanking and sourcing relationships provide a renewable and scalable supply of postpartum placentas. Its purpose-built cGMP-compliant manufacturing facility enables in-house production, reducing reliance on contract manufacturers and supporting scalability. The combination of proprietary technology, integrated manufacturing, and a differentiated product pipeline targeting aging-related diseases and longevity positions Celularity with competitive advantages in the regenerative medicine space. However, the company faces challenges including financial constraints and regulatory complexities that may impact its ability to fully capitalize on these advantages.

• Financial Sustainability Risk: The company has incurred net losses since inception, reported a net loss of $91.7 million for the year ended December 31, 2025, and has limited cash and liquidity ratios (current ratio 0.15, cash ratio 0.08) indicating significant financial constraints and substantial doubt about its ability to continue as a going concern without additional capital.
• Regulatory and Compliance Risk: Celularity has faced Nasdaq non-compliance notifications related to quarterly filing requirements and management changes, which may affect its listing status and investor confidence. The company operates in a highly regulated environment with complex clinical and approval pathways for cellular therapies and biomaterials.
• Operational and Execution Risk: The development and commercialization of novel cellular therapies and biomaterials involve significant scientific, clinical, and manufacturing challenges. The company must successfully advance its pipeline, scale manufacturing, and manage supply chain and regulatory complexities to achieve commercial success.
• Market and Competitive Risk: The regenerative medicine and longevity-focused therapeutic markets are competitive and rapidly evolving. Celularity must differentiate its products and maintain proprietary advantages to compete effectively against established and emerging players.

• Celularity Inc is a cellular and regenerative medicine company focused on advancing health longevity and redefining the standard of care for age-related diseases using novel therapies derived from the postpartum human placenta.
• The company develops off-the-shelf placental-derived allogeneic cellular therapy product candidates, including human placental-derived stem cells and mesenchymal-like allogeneic stromal cells (MLASCs), such as cenplacel-L, targeting multiple age-related degenerative diseases and conditions including immune, infectious diseases, and cancer.
• Celularity also develops and markets commercial-stage placental-derived biomaterial products for soft tissue repair and reconstructive procedures, including Biovance®, Biovance® 3L, Biovance® 3L Ocular, Interfyl®, CentaFlex®, and Rebound™.
• The company provides contract manufacturing and development services leveraging its expertise and a purpose-built 147,215 square foot cGMP-compliant facility in Florham Park, New Jersey, enabling scalable production of cellular therapies and biomaterials.
• Celularity's Celularity IMPACT platform integrates biosourcing, manufacturing, and cryopreservation of placental-derived allogeneic cells, aiming to deliver therapies with greater stemness, immunological naivete, and off-the-shelf availability compared to adult-derived cells.
• The company pursues longevity-focused therapeutic strategies addressing biological mechanisms of aging such as cellular senescence, stem cell exhaustion, and immune dysfunction.
• Celularity is expanding its biomaterials pipeline with new products including tendon wraps, bone void fillers, and placenta-derived extracellular matrices.
• The company is exploring investigational and ex-U.S. commercialization pathways for cellular therapies to enable earlier patient access and real-world data generation.
• Financial figures from the latest 10-K filed April 30, 2026, for the fiscal year ended December 31, 2025, show cash and cash equivalents of $6.175 million, current assets of $12.319 million, and current liabilities of $80.759 million, resulting in a current ratio of 0.15 and a cash ratio of 0.08.
• Net loss for the year ended December 31, 2025, was $91.7 million, with basic and diluted EPS of -$3.59 per share.
• The company has incurred net losses since inception and does not generate sufficient cash from operations to fund its business for the next twelve months, indicating substantial doubt about its ability to continue as a going concern without additional financing.
• Celularity has recently entered into an asset purchase and exclusive license agreement with NexGel, Inc. to license and sell six biomaterial products, with amended consideration totaling $13.3 million including upfront cash and a convertible promissory note.
• The company has faced Nasdaq non-compliance notifications related to quarterly filing requirements but has resolved listing compliance matters and resumed timely quarterly submissions.
• Celularity supports new Florida laws authorizing stem cell therapies for physicians and has partnered with Fountain Life to provide stem cell therapies under these regulations.
• The company announced termination of its CFO and appointment of an interim CFO in mid-2025.
• Celularity's Biovance and Biovance 3L products remain eligible for medical coverage under withdrawn Local Coverage Determinations (LCDs).